BRPI0520167A2 - formulaÇÕes aprimoradas de fenofibrato contendo mentol ou uma mistura de peg/poloxÂmero - Google Patents

formulaÇÕes aprimoradas de fenofibrato contendo mentol ou uma mistura de peg/poloxÂmero

Info

Publication number
BRPI0520167A2
BRPI0520167A2 BRPI0520167-5A BRPI0520167A BRPI0520167A2 BR PI0520167 A2 BRPI0520167 A2 BR PI0520167A2 BR PI0520167 A BRPI0520167 A BR PI0520167A BR PI0520167 A2 BRPI0520167 A2 BR PI0520167A2
Authority
BR
Brazil
Prior art keywords
menthol
mixture
poloxamer
peg
surfactant mixture
Prior art date
Application number
BRPI0520167-5A
Other languages
English (en)
Inventor
Moshe Flashner-Barak
E Itzhak Lerner
Vered Rosenberger
Noami Moldavski
Original Assignee
Teva Pharmaceutical Ind Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Ind Ltda filed Critical Teva Pharmaceutical Ind Ltda
Publication of BRPI0520167A2 publication Critical patent/BRPI0520167A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMULAÇÕES APRIMORADAS DE FENOFIBRATO CONTENDO MENTOL OU UMA MISTURA DE PEG/POLOXÂMERO. A invenção proporciona pelo menos uma composição para o tratamento de níveis elevados de triglicérides, consistindo de uma quantidade terapeuticaInente eficaz de fenofibrato ou outro fibrato intimamente associado ao mentol ou uma mistura surfactante, em que o mentol pode ser mentol ou mistura surfactante de mentol, e em que a mistura surfactante pode ser uma mistura de um polietileno glicol e um poloxâmero, tais como PEG (1000) e poloxâmero (407) A invenção também provê um método para o tratamento de níveis elevados de triglicérides em um sujeito, que consiste em administrar ao sujeito uma composição que consiste de uma quantidade terapeuticamente efetiva de fenofibrato ou outro fibrato e mentol ou uma mistura surfactante, em que o fenofibrato ou o outro fibrato está em associação intima com o mentol ou mistura surfactante, em que o mentol pode ser mentol ou mistura surfactante de mentol, e em que a mistura surfactante pode ser uma mistura de um polietileno glicol e um poloxâmero, tais como PEG (1000) e poloxâmero (407)
BRPI0520167-5A 2005-03-30 2005-12-29 formulaÇÕes aprimoradas de fenofibrato contendo mentol ou uma mistura de peg/poloxÂmero BRPI0520167A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66619205P 2005-03-30 2005-03-30
PCT/US2005/047676 WO2006107357A1 (en) 2005-03-30 2005-12-29 Improved formulations of fenofibrate containing menthol or a peg/poloxamer mixture

Publications (1)

Publication Number Publication Date
BRPI0520167A2 true BRPI0520167A2 (pt) 2009-04-22

Family

ID=35058530

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0520138-1A BRPI0520138A2 (pt) 2005-03-30 2005-07-18 formulações aprimoradas de fenofibrato contendo mentol ou peg/poloxámero
BRPI0520167-5A BRPI0520167A2 (pt) 2005-03-30 2005-12-29 formulaÇÕes aprimoradas de fenofibrato contendo mentol ou uma mistura de peg/poloxÂmero

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0520138-1A BRPI0520138A2 (pt) 2005-03-30 2005-07-18 formulações aprimoradas de fenofibrato contendo mentol ou peg/poloxámero

Country Status (12)

Country Link
US (1) US20060222706A1 (pt)
EP (2) EP1861084A1 (pt)
JP (2) JP2008505934A (pt)
KR (2) KR20070113289A (pt)
CN (3) CN101212962A (pt)
AU (2) AU2005330266A1 (pt)
BR (2) BRPI0520138A2 (pt)
CA (2) CA2601372A1 (pt)
EA (2) EA200701750A1 (pt)
IL (2) IL185735A0 (pt)
MX (2) MX2007011858A (pt)
WO (2) WO2006107316A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2540984C (en) 2003-10-10 2011-02-08 Lifecycle Pharma A/S A solid dosage form comprising a fibrate
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
MXPA06003813A (es) * 2003-10-10 2006-06-14 Lifecycle Pharma As Forma solida de dosificacion que comprende un fibrato y una estatina.
US7915247B1 (en) 2006-08-21 2011-03-29 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid
JP5186159B2 (ja) * 2006-08-31 2013-04-17 あすか製薬株式会社 フェノフィブラート含有組成物
JP2013047282A (ja) * 2006-08-31 2013-03-07 Aska Pharmaceutical Co Ltd フェノフィブラート含有組成物
US20110097414A1 (en) * 2007-02-26 2011-04-28 Sandal Roshan Lal Pharmaceutical compositions comprising adsorbate of fenofibrate
AU2009292615B2 (en) * 2008-09-17 2015-12-03 Mylan Inc. Granulates, process for preparing them and pharmaceutical products containing them
US8632846B2 (en) * 2010-09-17 2014-01-21 Medtronic Vascular, Inc. Apparatus and methods for loading a drug eluting medical device
JP6149865B2 (ja) * 2011-12-14 2017-06-21 エルテーエス ローマン テラピー−ジステーメ アーゲー フェノフィブラートのための強化された溶解速度を備えたウェーハ及びカプセル製剤
WO2014091318A1 (en) 2012-12-11 2014-06-19 Lupin Atlantis Holdings, S.A. Reduced dose pharmaceutical compositions of fenofibrate

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
FR2737121B1 (fr) * 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6814977B1 (en) * 1998-12-18 2004-11-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US6383517B1 (en) * 1999-01-29 2002-05-07 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6719999B2 (en) * 1999-03-31 2004-04-13 Abbott Laboratories Formulations comprising lipid-regulating agents
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
EP1175205B1 (en) * 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
WO2001051089A1 (de) * 2000-01-13 2001-07-19 Merck Patent Gmbh Pharmazeutische zubereitungen enthaltend 2-pyrrolidon als lösungsvermittler
ATE367802T1 (de) * 2000-09-20 2007-08-15 Jagotec Ag Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
KR20040098023A (ko) * 2002-03-26 2004-11-18 테바 파마슈티컬 인더스트리즈 리미티드 약물 미세입자
US20040005339A1 (en) * 2002-06-28 2004-01-08 Shojaei Amir H. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
WO2004073686A2 (en) * 2003-02-20 2004-09-02 Teva Pharmaceutical Industries Ltd. Menthol solutions of drugs
MXPA06003813A (es) * 2003-10-10 2006-06-14 Lifecycle Pharma As Forma solida de dosificacion que comprende un fibrato y una estatina.
CA2540984C (en) * 2003-10-10 2011-02-08 Lifecycle Pharma A/S A solid dosage form comprising a fibrate
US20050096390A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
WO2006037348A1 (en) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and a statin

Also Published As

Publication number Publication date
JP2008505934A (ja) 2008-02-28
EA200701986A1 (ru) 2008-04-28
BRPI0520138A2 (pt) 2011-04-19
CN101217951A (zh) 2008-07-09
WO2006107316A8 (en) 2007-11-22
KR20070113289A (ko) 2007-11-28
CN101217950A (zh) 2008-07-09
WO2006107316A1 (en) 2006-10-12
CA2601372A1 (en) 2006-10-12
WO2006107357A1 (en) 2006-10-12
CN101212962A (zh) 2008-07-02
US20060222706A1 (en) 2006-10-05
AU2005330320A1 (en) 2006-10-12
EA200701750A1 (ru) 2008-02-28
IL185735A0 (en) 2008-01-06
EP1861084A1 (en) 2007-12-05
IL185734A0 (en) 2008-01-06
KR20070120990A (ko) 2007-12-26
JP2008534584A (ja) 2008-08-28
CA2601374A1 (en) 2006-10-12
MX2007012125A (es) 2007-12-07
EP1707196A1 (en) 2006-10-04
AU2005330266A1 (en) 2006-10-12
MX2007011858A (es) 2008-03-25

Similar Documents

Publication Publication Date Title
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
BRPI0520167A2 (pt) formulaÇÕes aprimoradas de fenofibrato contendo mentol ou uma mistura de peg/poloxÂmero
AR055095A1 (es) Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c
ATE538801T1 (de) Therapeutische zusammensetzungen mit mindestens einem pyrrolobenzodiazepin-derivat und fludarabin
PL1824563T3 (pl) Kompozycje zawierające ornitynę i fenylooctan lub fenylomaślan do leczenia encefalopatii wątrobowej
ATE548034T1 (de) Pharmazeutische zusammensetzungen mit droxidopa
WO2008103993A3 (en) Compositions and methods for treating glycogen storage diseases
MX2009008022A (es) Metodos y composiciones para tratar neuropatias.
AR065138A1 (es) Uso de compuestos de arsenico para el tratamiento del dolor y la inflamacion
AR067495A1 (es) Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco
JO3598B1 (ar) الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
BR112022004587A2 (pt) Métodos para tratar narcolepsia tipo 1, diminuir eventos tipo cataplexia, aumentar concentração de cálcio intracelular, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, tratar uma doença associada a nível de orexina reduzido, aumentar alerta, melhorar classificação de escala de sonolência epworth, e, composição farmacêutica
CO6331301A2 (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
PE20080331A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
DK1392329T3 (da) Anvendelse af sulodexid til behandling af inflammatorisk tarmsygdom
BRPI0414481A (pt) métodos de tratamento ou de prevenção da sìndrome das pernas inquietas em um paciente e de melhoria do sono em um paciente com sìndrome das pernas inquietas, e, composição farmacêutica
BR112018072339A2 (pt) tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados
SV2003000752A (es) Combinacion de agonistas de gaba e inhibidores de aldosa-reductasa ref. pc11830/700020/bb
EA200701751A1 (ru) Улучшенные составы фенофибрата
MX2021014561A (es) Uso de una composicion de albumina con o sin agentes pro-emt y anti-emt (agentes para prevenir o minimizar la transicion epitelio mesenquima emt), para el tratamiento de enfermedades o afecciones de hemorragias, quemaduras, disfuncion hepatica, cancer, etc.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2203 DE 26/03/2013.